How a Long-Term Investor Is Approaching Transmedics Stock After It PLUNGES
1 extracted signal · 1 resolved · 0 still active
Brian StoffelIndependent analyst profile- Source published
- 05 May 2026, 23:02 UTC
- Recorded by Tahlil Plus
- 30 Jul 2026, 03:49 UTC
AI-generated source summary
TransMedics, Inc. (TMDX) experienced a significant stock drop following its Q1 2026 earnings report. Despite a 21% year-over-year revenue increase to $174 million, the company missed analyst estimates of $175 million. This miss, coupled with a 32% increase in the cost of revenue (leading to a lower gross margin from 81% to 77.5%) and a 45% jump in operating expenses, contributed to a 51% decrease in operating income, landing at $27 million compared to $55 million year-over-year. The company's revised long-term guidance projects 20,000 to 30,000 transplants by the end of 2030, a significant increase from previous guidance of 10,000 by 2028. This revised guidance is contingent on approvals for its heart and kidney transplant technologies and successful scaling of its operational infrastructure. The current market capitalization stands at $2.5 billion, with an implied five-year CAGR of 35.2% to reach a projected blended potential of $11.3 billion by 2030 based on management's targets. However, the recent earnings miss and rising costs present near-term headwinds.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Brian Stoffel
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.